Intra-Cellular Therapies Secures New Credit Facility
| Field | Detail |
|---|---|
| Company | Intra-Cellular Therapies, Inc. |
| Form Type | 8-K |
| Filed Date | Mar 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, credit-agreement
Related Tickers: ITCI
TL;DR
ITCI just got a new credit line for general corporate stuff.
AI Summary
Intra-Cellular Therapies, Inc. announced on March 18, 2025, that it has entered into a new credit agreement. The company, previously known as Oneida Resources Corp., will use the proceeds from this agreement for general corporate purposes. The filing does not specify the exact amount of the credit facility.
Why It Matters
This new credit agreement provides Intra-Cellular Therapies with financial flexibility for its ongoing operations and potential future growth initiatives.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of a credit agreement and does not indicate any immediate financial distress or significant new risks.
Key Players & Entities
- Intra-Cellular Therapies, Inc. (company) — Registrant
- Oneida Resources Corp. (company) — Former company name
- March 18, 2025 (date) — Date of report
FAQ
What is the purpose of the new credit agreement for Intra-Cellular Therapies, Inc.?
The new credit agreement is for general corporate purposes.
When was this Form 8-K filed?
This Form 8-K was filed on March 18, 2025.
What was Intra-Cellular Therapies, Inc. formerly known as?
Intra-Cellular Therapies, Inc. was formerly known as Oneida Resources Corp.
In which state is Intra-Cellular Therapies, Inc. incorporated?
Intra-Cellular Therapies, Inc. is incorporated in Delaware.
What is the principal executive office address for Intra-Cellular Therapies, Inc.?
The principal executive office address is 135 Route 202/206 Suite 6, Bedminster, NJ 07921.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 18, 2025 regarding Intra-Cellular Therapies, Inc..